This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Bio Pharma Dive
AUGUST 3, 2020
Seeking fast answers in a pandemic, Lilly will use mobile RVs to set up infusion clinics at assisted living facilities, which have become COVID-19 hot spots.
337 
Bio Pharma Dive
JANUARY 20, 2021
Results from a clinical trial in nursing home residents and staff offered the first evidence Lilly's bamlanivimab could protect against, as well as treat, COVID-19
281
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NY Times
JANUARY 21, 2021
A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.
105 
NY Times
JANUARY 21, 2021
A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.
98 
pharmaphorum
OCTOBER 27, 2020
According to Lilly, the NIAID took its decision on the strength of trial data which indicated that bamlanivimab – an antibody that neutralises the SARS-CoV-2 coronavirus – was unlikely to help hospitalised patients recover from advanced-stage COVID-19. The post NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial appeared first on.
105 
pharmaphorum
JUNE 15, 2021
Antibody flunks post-exposure prevention study. Eli Lilly meanwhile reported positive results with its bamlanivimab antibody in the BLAZE-2 study carried put in nursing homes, which found a 57% reduction in the risk of infection compared to placebo.
119 
pharmaphorum
OCTOBER 28, 2020
Our goal is to ensure that Lilly antibody treatments are available to patients who need them, no matter where they live. “As As long as supply of neutralising antibodies is constrained, we believe the only way to ensure equitable access is for Lilly to contract directly with governments and pan-national philanthropic organisations. “As
104 
pharmaphorum
AUGUST 3, 2020
While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in high-risk locations. The post Lilly’s antibody for COVID-19 protection starts nursing home trial appeared first on.
59 
pharmaphorum
FEBRUARY 10, 2021
The FDA has granted an emergency licence for Eli Lilly’s COVID-19 antibody combination therapy, to reduce chances of high-risk patients progressing from mild to moderate disease to more severe symptoms that may need hospital treatment. There are a range of other antibody therapies in various stages of development.
96 
BioSpace
JANUARY 20, 2021
Protecting the most vulnerable, Eli Lilly’s bamlanivimab significantly reduced COVID-19 risk for nursing home residents in a Phase III trial.
105 
pharmaphorum
SEPTEMBER 16, 2020
Regeneron’s COVID-19 antibody cocktail has been added to the UK’s RECOVERY trial, one of the largest of its kind in the world that is testing several potential coronavirus therapies at the same time. REGN-COV2 is a combination of two monoclonal antibodies, designed to block infections of SARS-CoV-2, the virus that causes COVID-19.
98 
The Pharma Data
JANUARY 22, 2021
Antibody Drug May Protect Nursing Home Residents, Staff From COVID-19. 22, 2021 — An antibody drug that has emergency use authorization from the U.S. It was conducted to find out if bamlanivimab could protect nursing home residents and staff against infections with the new coronavirus, The New York Times reported.
52 
Medical Xpress
FEBRUARY 27, 2023
Every four months, pathologist Aaron LeBeau scoops into a net one of the five nurse sharks he keeps in his University of Wisconsin lab. Then he carefully administers a shot to the animal, much like a pediatrician giving a kid a vaccine.
98 
The Pharma Data
JANUARY 21, 2021
Eli Lilly reported yesterday that its monoclonal antibody bamlanivimab (LY-CoV555) significantly lessened the risk of contracting COVID-19 among nursing home residents and staff, according to findings from a phase 3 trial. James Miessler. Source link.
52 
The Pharma Data
FEBRUARY 1, 2021
1, 2021 — As America’s vaccination campaign begins to gain momentum, a promising sign has emerged: Federal data shows that coronavirus cases in nursing homes have declined over the past four weeks. The country recorded 17,584 cases in nursing homes during the week ending Jan. MONDAY, Feb.1, 17, The New York Times reported.
52 
The Pharma Data
NOVEMBER 26, 2020
26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. Study will expand access to antibody testing outside of laboratory settings. CHICAGO , Nov.
52 
pharmaphorum
AUGUST 7, 2020
Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by year-end. Gillead lost $3.3bn in Q2, with the company blaming COVID-19 and its acquisition of immune-oncology company Forty Seven for the fall.
105 
The Pharma Data
JANUARY 26, 2021
Vir Biotechnology , Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate Vir’s investigational monoclonal antibody, VIR-7831, in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate COVID-19. Eli Lilly’s bamlanivimab targets different sites on the SARS-CoV-2 spike protein.
52 
Scienmag
APRIL 6, 2021
Major boost in COVID-19 antibodies seen in breast milk after vaccination Nursing mothers who receive a COVID-19 vaccine may pass protective antibodies to their babies through breast milk for at least 80 days following vaccination, suggests new research from Washington University School of Medicine in St.
49 
The Pharma Data
JANUARY 12, 2021
million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. Under the new agreement, the government will purchase all finished doses of the casirivimab and imdevimab antibody cocktail delivered by June 30, 2021 , up to 1.25 TARRYTOWN, N.Y. , 12, 2021 /PRNewswire/ — . million doses.
52 
Scienmag
DECEMBER 10, 2020
PPE keeps most workers safe in acute hospital exposures Nurses only group with higher risk once community exposure considered Largest cohort of health care worker risk for SARS CoV-2 Only high-flow oxygen therapy and hemodialysis linked to more antibodies to SARS-CoV-2 CHICAGO — In a well-resourced health system with adequate PPE (Personal Protection (..)
52 
The Pharma Data
DECEMBER 29, 2020
First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. futility analysis).
52 
The Pharma Data
NOVEMBER 20, 2020
NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. TARRYTOWN, N.Y., November 21, 2020 – Regeneron Pharmaceuticals, Inc.
52 
The Pharma Data
DECEMBER 17, 2020
NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.
52 
The Pharma Data
NOVEMBER 18, 2020
Eli Lilly and Company’s antibody therapeutic will be distributed as part of the federal government’s Operation Warp Speed. . 18, 2020 /PRNewswire/ — Tampa General Hospital provided the first monoclonal antibody treatment to a COVID-19 positive patient today. TAMPA, Fla., Have diabetes.
40 
Bioengineer
JULY 23, 2021
The LOTIS-2 trial tested the efficacy of Loncastuximab tesirine, an antibody-drug complex that targets CD19 – the same molecule targeted on the lymphoma B-cells by CAR-T therapy. The state’s leader in obtaining biomedical research funds, in fiscal year 2019, MUSC set a new high, bringing in more than $284 million.
52 
pharmaphorum
JANUARY 24, 2022
The regulator said that Veklury could be provided to eligible patients “at skilled nursing facilities, home healthcare settings and outpatient facilities such as infusion centres.” ” It would have to be delivered as a daily intravenous infusion in these outpatient setting over three days.
98 
The Pharma Data
JANUARY 26, 2021
. “These exciting results, which replicate positive Phase 2 data in a much larger set of patients, add valuable clinical evidence about the role neutralizing antibodies can play in fighting this pandemic. Lilly’s chief scientific officer and president of Lilly Research Laboratories. have reached record highs.
52 
The Pharma Data
NOVEMBER 21, 2020
NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. government allocation program. Regeneron Pharmaceuticals, Inc.
40 
Eye on FDA
DECEMBER 15, 2021
We have the emergence of monoclonal antibodies and protease inhibitors being utilized or being considered as treatments for various stages of disease. We even have a pile of misinformation.
72 
pharmaphorum
SEPTEMBER 8, 2021
. “Because NHS staff and resources are scarce, another national mobilisation would potentially leave us with fewer resources for cancer screenings and the other care provided by doctors and nurses each day,” says the AZ executives. ” The post AZ CEO Soriot urges caution on COVID booster doses appeared first on.
83 
XTalks
JUNE 4, 2024
Today, there’s been a shift towards more complex, large molecules or biologics like monoclonal antibodies, antibody-drug conjugates (ADCs) and advanced therapies like RNA-based treatments and cell and gene therapies. In the past, the majority of drugs evaluated in the clinical pharmacology space were small molecules.
The Pharma Data
SEPTEMBER 7, 2021
The vaccine currently being tested stimulates the body’s immune system to produce antibodies to oxycodone. If someone who has been vaccinated takes oxycodone, those antibodies would bind to the drug molecule, stopping it from entering the brain and, ultimately, preventing the “high” produced by the drug. .
The Pharma Data
OCTOBER 18, 2020
Since then, Eurofins has rolled out several highly sensitive and specific assays to thousands of clients nationwide, including hospitals, physicians’ offices, nursing homes, government entities, sports organizations and employers.
52 
XTalks
JANUARY 5, 2021
These include monoclonal antibody drugs, which are attractive therapeutic agents owing to their targeted specificity. Eli Lilly’s bamlanivimab and Regeneron’s monoclonal antibody cocktail REGEN-COV2 which consists of two monoclonal antibodies, casirivimab and imdevimab, were approved in 2020 for use in the treatment of COVID-19 patients.
98 
The Pharma Data
NOVEMBER 6, 2020
Finally, Dr. Balmuri and colleagues included the rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody status from patients’ diagnostic lab results as indicators of disease severity. The patients were seven years of age, on average. The global standard total knee replacement was developed at HSS in 1969.
52 
XTalks
JANUARY 8, 2024
There, it specifically targets the mucosal B cells in the ileum to inhibit antibody formation. Engineered for delayed release, Tarpeyo is designed to maintain its structure until it arrives at the ileum of the digestive tract.
64 
The Pharma Data
MAY 27, 2022
4] This CMA was supported by the pivotal CARTITUDE-1 study, including patients who had received a median of six prior treatment regimens (range, 3–18), and had previously received an IMiD, PI, and an anti-CD38 monoclonal antibody.1 In December 2017, Janssen Biotech, Inc. to develop and commercialise cilta-cel.[1].
52 
The Pharma Data
APRIL 8, 2021
Roche will present data on the increased use of home nursing capabilities in the Phase III GRADUATE studies of gantenerumab during the COVID-19 pandemic, which enabled home-bound trial participants to continue dosing to maintain medicine exposure. P1: Aging and Dementia: Biomarkers. Gantenerumab for Alzheimer’s Disease.
Pfizer
JANUARY 27, 2023
This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern. A transient decrease in body weight was observed in the nursing offspring of rats administered nirmatrelvir.
112 
The Pharma Data
JANUARY 24, 2021
National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes. All participants randomized to receive either 4,200 mg of bamlanivimab, Lilly’s neutralizing antibody, or placebo. Non-COVID-19-Related.
52 
The Pharma Data
NOVEMBER 4, 2020
It is important to show this card to any doctor or nurse to help them diagnose and treat you quickly. adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. It is important to show this card to any doctor or nurse to help them diagnose and treat you quickly.
52 
pharmaphorum
DECEMBER 23, 2022
There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Side effects and cost implications. Oral therapy data presented at ASH. CellCentric, a U.K-based
52 
XTalks
AUGUST 30, 2022
Such therapies may involve small interfering RNA (siRNA) or oligonucleotides in viral transfection platforms, large molecules and antibodies. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets? Vornov, nusinersen is driving much of what is being currently seen in drug development.
83
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content